Sistema de Salut de Catalunya
Institut Català de la Salut
[Villavicencio A] Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona, Spain. Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. [Solans M] Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Zacarías-Pons Ll] Research Group on Aging, Disability and Health, Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Vidal A, Puigdemont M] Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona, Spain. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. [Roncero JM] Departament d’Hematologia, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Saez M] Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Marcos-Gragera R] Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona, Spain. Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Josep Carreras Leukemia Research Institute, Badalona, Spain
Hospital Universitari de Girona Dr Josep Trueta
2023-03-17T10:47:38Z
2023-03-17T10:47:38Z
2021-01-15
Leucèmia limfocítica crònica; Comorbiditat; Causes de mort
Chronic lymphocytic leukemia; Comorbidity; Cause of death
Leucemia linfocítica crónica; Comorbilidad; Causas de muerte
This study aimed to examine the prevalence of comorbidities in patients diagnosed with chronic lymphocytic leukemia (CLL), and to assess its influence on survival and cause-specific mortality at a population-based level. Incident CLL cases diagnosed in the Girona province (Spain) during 2008-2016 were extracted from the Girona Cancer Registry. Rai stage and presence of comorbidities at diagnosis, further categorized using the Charlson comorbidity index (CCI), were obtained from clinical records. Observed (OS) and relative survival (RS) were estimated and Cox's proportional hazard models were used to explore the impact of comorbidity on mortality. Among the 400 cases included in the study, 380 (99.5%) presented at least one comorbidity at CLL diagnosis, with diabetes without end organ damage (21%) being the most common disease. 5-year OS and RS were 68.8 (95% CI: 64.4-73.6) and 99.5 (95% CI 3.13-106.0), respectively, which decreased markedly with increasing CCI, particularly in patients with CCI ≥ 3. Multivariate analysis identified no statistically significant association between the CCI and overall CLL-related or CLL-unrelated mortality. In conclusion, a high CCI score negatively influenced the OS and RS of CLL patients, yet its effect on mortality was statistically non-significant when also considering age and the Rai stage.
We thank CERCA programme/Generalitat de Catalunya for institutional support. Thiswork was supported by Spanish Ministry of Economy and Competitiveness—Carlos III Instituteof Health co-funded by FEDER funds/European Regional Development Fund (ERDF)—A way tobuild Europe (PI11/02213, PI15/00966 and CIBERESP); and with the support of the Secretariat forUniversities and Research of the Ministry of Business and Knowledge of the Government of Catalonia(2017-SGR-733). IDIBGI is a member of the CERCA Programme, Generalitat de Catalunya.
Article
Published version
English
Leucèmia limfoide - Epidemiologia; Mort - Causes; Comorbiditat; DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Lymphoid::Leukemia, B-Cell::Leukemia, Lymphocytic, Chronic, B-Cell; Other subheadings::Other subheadings::Other subheadings::/epidemiology; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Cause of Death; HEALTH CARE::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Comorbidity; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia de células B::leucemia linfocítica crónica de células B; Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología; ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::factores epidemiológicos::comorbilidad; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::mortalidad::causas de muerte
MDPI
International Journal of Environmental Research and Public Health;18(2)
https://doi.org/10.3390/ijerph18020701
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
